CN103347406B - 使用β-羟基-β-甲基丁酸盐改善脑部发育和认知功能的方法 - Google Patents

使用β-羟基-β-甲基丁酸盐改善脑部发育和认知功能的方法 Download PDF

Info

Publication number
CN103347406B
CN103347406B CN201280009207.4A CN201280009207A CN103347406B CN 103347406 B CN103347406 B CN 103347406B CN 201280009207 A CN201280009207 A CN 201280009207A CN 103347406 B CN103347406 B CN 103347406B
Authority
CN
China
Prior art keywords
hmb
nutritional
hydroxy
methylbutyrate
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280009207.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN103347406A (zh
Inventor
J.M.L.佩罗萨
M.M.马丁
A.B.佩雷斯
M.R.冈萨雷斯
R.R.卡布雷拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Publication of CN103347406A publication Critical patent/CN103347406A/zh
Application granted granted Critical
Publication of CN103347406B publication Critical patent/CN103347406B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Pediatric Medicine (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN201280009207.4A 2011-02-17 2012-02-13 使用β-羟基-β-甲基丁酸盐改善脑部发育和认知功能的方法 Expired - Fee Related CN103347406B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161443762P 2011-02-17 2011-02-17
US61/443762 2011-02-17
US61/443,762 2011-02-17
PCT/US2012/024817 WO2012112419A1 (en) 2011-02-17 2012-02-13 Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate

Publications (2)

Publication Number Publication Date
CN103347406A CN103347406A (zh) 2013-10-09
CN103347406B true CN103347406B (zh) 2015-08-05

Family

ID=45757211

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280009207.4A Expired - Fee Related CN103347406B (zh) 2011-02-17 2012-02-13 使用β-羟基-β-甲基丁酸盐改善脑部发育和认知功能的方法

Country Status (12)

Country Link
US (1) US9326956B2 (enExample)
EP (1) EP2675298A1 (enExample)
JP (2) JP6034309B2 (enExample)
CN (1) CN103347406B (enExample)
AR (1) AR085297A1 (enExample)
BR (1) BR112013020643A2 (enExample)
CA (1) CA2825734C (enExample)
MX (1) MX348708B (enExample)
PH (1) PH12013501671A1 (enExample)
SG (1) SG192813A1 (enExample)
TW (1) TWI565420B (enExample)
WO (1) WO2012112419A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG182808A1 (en) 2010-01-29 2012-09-27 Abbott Lab Aseptically packaged nutritional liquids comprising hmb
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
RU2012125881A (ru) 2010-01-29 2014-03-10 Эбботт Лэборетриз Питательные эмульсии, содержащие бета-гидрокси-бета-метилбутират кальция (гмб кальция)
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
CN103347406B (zh) 2011-02-17 2015-08-05 雅培制药有限公司 使用β-羟基-β-甲基丁酸盐改善脑部发育和认知功能的方法
ES2421187B1 (es) * 2012-02-23 2014-11-26 Abbott Laboratories Metodo para mejorar el desarrollo cerebral y la funcion cognitiva usando beta-hidroxi-beta-metilbutirato
EP2745708A1 (en) * 2012-12-24 2014-06-25 Abbott Laboratories, Inc. Antidepressant effect of ß-hydroxy-ß-methylbutyrate
US20150351438A1 (en) * 2013-01-29 2015-12-10 Otc Nutrition Llc Micronutrient Fortification Delivery
WO2014127112A1 (en) * 2013-02-13 2014-08-21 Baylor College Of Medicine Memory enhancer and actin dynamics
SG11201507128UA (en) * 2013-03-15 2015-10-29 Abbott Lab Low calorie infant formula containing
WO2015148982A1 (en) * 2014-03-27 2015-10-01 Winterfield Roland W Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy
WO2017048708A1 (en) * 2015-09-16 2017-03-23 Abbott Laboratories Reduced fat, shelf stable liquid nutritional composition
DK3373740T3 (da) * 2015-11-10 2021-05-25 Metabolic Tech Inc Sammensætninger og fremgangsmåder til anvendelse af -hydroxy-methylbutyrat (hmb) som et dyrefoderadditiv
JP7011300B2 (ja) * 2017-12-19 2022-02-10 株式会社島田製薬 ＨＭＢＣａ含有顆粒の製造方法、及びサプリメント

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006062424A2 (en) * 2004-11-08 2006-06-15 Sgp & Sons Ab Use of 3-hydroxy-3-methylbutyrate alone or in combination with alpha-ketoglutarate in the growth and mineralisation of the osteo-skeletal system
CN101785566A (zh) * 2010-01-22 2010-07-28 北京康比特体育科技股份有限公司 一种含有hmb的运动饮料

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291525B1 (en) 1999-09-08 2001-09-18 Iowa State University Research Foundation, Inc. Method for improving a human's perception of his emotional state
US7445807B2 (en) 2002-10-15 2008-11-04 Western Holdings, Llc Agglomerated granular protein-rich nutritional supplement
US20050027005A1 (en) 2003-08-02 2005-02-03 Matthias Boldt Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner
US20050215640A1 (en) 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
US20060167075A1 (en) 2005-01-25 2006-07-27 Pearson James P Modulators of FAAH
EP1973426A2 (en) * 2005-11-03 2008-10-01 Southwest Immunology Inc. Compositions for preventing and reducing delayed onset muscle soreness
ES2548432T3 (es) * 2005-12-19 2015-10-16 Abbott Laboratories Uso de beta-hidroxi-beta-metilbutirato para modular el desequilibrio en la producción de citoquinas de tipo 1 y tipo 2
JP5630750B2 (ja) * 2008-03-18 2014-11-26 国立大学法人 岡山大学 興奮性化学伝達調節剤およびそのスクリーニング法
EP2381784B1 (en) 2008-12-09 2018-07-11 Metabolic Technologies, Inc. Nutritional intervention for improving muscular function and strength
JP2009155336A (ja) * 2009-03-31 2009-07-16 Tsujido Chemical Corp 治療剤
TW201117736A (en) 2009-11-17 2011-06-01 Hui-Chiang Lu Compositions for sport supplement
SG191315A1 (en) 2010-12-22 2013-07-31 Abbott Lab Nutritional products comprising calcium beta-hydroxy-beta methylbutyrate and conjugated linoleic acid
SG191369A1 (en) 2010-12-27 2013-08-30 Abbott Lab Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate
CN103347406B (zh) 2011-02-17 2015-08-05 雅培制药有限公司 使用β-羟基-β-甲基丁酸盐改善脑部发育和认知功能的方法
WO2013142424A1 (en) 2012-03-19 2013-09-26 Abbott Laboratories Beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance
MX2015003498A (es) 2012-09-17 2015-06-04 Abbott Lab Composiciones que contienen acido beta-hidroxi-beta-metilbutirico y usos de las mismas.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006062424A2 (en) * 2004-11-08 2006-06-15 Sgp & Sons Ab Use of 3-hydroxy-3-methylbutyrate alone or in combination with alpha-ketoglutarate in the growth and mineralisation of the osteo-skeletal system
CN101785566A (zh) * 2010-01-22 2010-07-28 北京康比特体育科技股份有限公司 一种含有hmb的运动饮料

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
补充β-羟基-β甲基丁酸盐(HMB)在运动训练中的生理效应;曾志刚等;《中国运动医学杂志》;20070110;第26卷(第01期);第120－123页 *

Also Published As

Publication number Publication date
JP6340394B2 (ja) 2018-06-06
US9326956B2 (en) 2016-05-03
JP6034309B2 (ja) 2016-11-30
US20140249223A1 (en) 2014-09-04
PH12013501671A1 (en) 2021-06-02
BR112013020643A2 (pt) 2016-08-02
CA2825734C (en) 2016-05-17
EP2675298A1 (en) 2013-12-25
WO2012112419A1 (en) 2012-08-23
TWI565420B (zh) 2017-01-11
SG192813A1 (en) 2013-09-30
AR085297A1 (es) 2013-09-18
CA2825734A1 (en) 2012-08-23
JP2014506890A (ja) 2014-03-20
MX348708B (es) 2017-06-26
MX2013009528A (es) 2013-10-01
WO2012112419A8 (en) 2014-03-06
CN103347406A (zh) 2013-10-09
JP2017061483A (ja) 2017-03-30
TW201309212A (zh) 2013-03-01

Similar Documents

Publication Publication Date Title
CN103347406B (zh) 使用β-羟基-β-甲基丁酸盐改善脑部发育和认知功能的方法
AU2021202459C1 (en) Nutritional product
EP2685961B1 (en) Method for treating neurotrauma
US10864281B2 (en) Inclusion complexes and methods for making the same
US20050147665A1 (en) Pharmaceutical and nutritional compositions
US20160250169A1 (en) Compositions and methods for improving cognitive function
CN105407744A (zh) 含有β-羟基-β-甲基丁酸的低卡路里婴儿配方
KR20240057401A (ko) 파라잔틴-기반 카페인 대용 조성물 및 느린 카페인 대사자에서의 이의 사용 방법
TW201524372A (zh) 用於提升認知能力的方法及組合物
BR102022006625A2 (pt) Suplemento alimentar e seu uso
EP4353261A1 (en) Nutraceutic combination and its use in the treatment of neurological disorders
Daly et al. Protein substitutes in PKU; their historical evolution. Nutrients. 2021; 13: 484
US20150352071A1 (en) Methods for reducing muscle soreness after exercise using beta-hydroxy-beta-methylbutyrate
US20210236521A1 (en) Method For Improving Brain Function And A Dietary Supplement For Use In The Method
US20150250813A1 (en) Dietary supplement containing phospholipid-dha, folate, and n-acetyl-l-cysteine
ES2421187A1 (es) Metodo para mejorar el desarrollo cerebral y la funcion cognitiva usando beta-hidroxi-beta-metilbutirato
HK1208367B (en) Nutritional product comprising decanoic acid and octanoic acid

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: J.M.L.Perosa

Inventor after: M.M.Martin

Inventor after: A.B.Peres

Inventor after: M.R.Gonzales

Inventor after: R.R.Cabrera

Inventor before: J.M.L.Perosa

Inventor before: M.M.Martin

Inventor before: A.B.Peres

Inventor before: M.R.Gonzales

Inventor before: R.R.Kenbuleila

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: J. M. L. PEDROSA M. M. MA DING A. B. PEREZ M. R. GONZALEZ R. R. CANBRERA TO: J. M. L. PEDROSA M. M. MA DING A. B. PEREZ M. R. GONZALEZ R. R. CABRERA

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150805

Termination date: 20190213